Osteoprotegerin and Diabetes-Associated Pathologies

Abstract

Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.

The effect of bariatric surgery on serum TRAIL and osteoprotegerin levels in obesity complicated by glucose disorders

“…Altered circulating osteoprotegerin levels are linked with metabolic disease, however whether osteoprotegerin may be implicated in obesity remains an open question, given the conflicting data between published studies [12]. Osteoprotegerin also appears to play a role in diabetes outcomes, such that osteoprotegerin levels are higher in T2D [26], and can predict mortality [27]. Here, we found that circulating osteoprotegerin levels are significantly reduced 2 and 12 weeks after bariatric surgery.…”

Osteoprotegerin in Exosome-Like Vesicles from Human Cultured Tubular Cells and Urine

“…Fetuin, another factor that prevents vascular calcification, was recently reported to be present in kidney-derived exosomes [5]. The presence of OPG in circulating microvesicles should be explored since plasma OPG is associated with increased cardiovascular risk [51], [52].…”

Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

“…Emerging evidence suggests that abdominal obesity, IR, and NAFLD are associated with decreased osteoprotegerin levels [36,37].…”